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a B S t r a C t
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current 
available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. 
Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration. The 
italian Study Group for Cutaneous annexial disease of the italian Society of dermatology proposes these italian guidelines for diagnosis and 
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Diagnosis
the initial clinical examination should seek basic evidence 
for the diagnosis of AA, as well as screening for associated 
autoimmune diseases.
Major objectives
• to confirm the clinical diagnosis of AA, differentiat-
ing from other causes of hair loss;
• to specify the extent and location of hair loss involve-
ment;
• to assess the activity of the disease by trichoscopy;
• to evaluate the prognosis depending on prognostic 
factors;
• to evaluate other associated conditions (Hashimoto 
thyroiditis, coeliac disease, etc.);
• to start treatment.
Clinical examination and differentials
Medical history
• it should specify the age of the first onset of hair loss 
and duration of the current episode;
• it should specify any associated symptoms (pain, pru-
ritus);
• it should include a detailed medical history and drug 
intake (including response to therapy for aa);
• it should include a complete family medical history 
investigating autoimmune disorders;
• it should seek to evaluate the disease impact on pa-
tient’s quality of life (dlQi).
Physical examination
AA typically presents with single or multiple round or oval 
patches of hair loss configuring (1) patchy alopecia. Other 
presentations include (2) alopecia totalis characterized by 
complete loss of scalp hair and (3) alopecia universalis 
characterized by loss of all body and scalp terminal hair; 
rarely various pattern of hair loss can be detected such as 
(4) ophiasis pattern: band-like pattern of hair loss along 
the periphery of occipital and temporal scalp, (5) ophiasis 
inversus-sisaipho pattern: band-like hair loss in the fronto-
Introduction
alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. it has 
an unpredictable chronic-relapsing course, leading to tran-
sient non-scarring hair loss. Clinically, presentations vary 
considerably between individuals, ranging from small 
patches of alopecia to the loss of all body hair: alopecia 
universalis.1
Prevalence of aa has been estimated to about 0,2% of 
the general population and approximately 1.7-2.1% of the 
population experiences an episode of aa during their life-
time.2 AA can start at any age, however in the majority 
of patients, the onset is within the first three decades of 
life. there is none race or sex predilection. aa is often 
associated with other autoimmune diseases that must be 
investigated.
in most patients, disease severity is closely correlated 
with psychologic distress, and management of AA should 
include psychological support. the course of aa is not 
predictable, as spontaneous remission is possible, as well 
as a chronic course not responding to therapy. Up to 50 
percent of patients with patchy AA experience spontane-
ous hair regrowth within one year, however, most will re-
lapse months or years after remission.3
due to the variable course of aa and the different degree 
of severity of hair loss, only a few well-designed reliable 
clinical trials are available in AA, which are limited by the 
low numbers of patients studied.4 The primary objective of 
the italian guidelines is to make recommendations on the 
best treatment of aa to the italian dermatological commu-
nity, in collaboration with the expert in the field.
Methodology of guideline preparation
these guidelines are designed under the guidance of ital-
ian Study Group on Cutaneous annexial disease of the 
italian Society of dermatology (SidemaSt), taking in 
mind italian regulations and treatments available.
this article summarizes evidence-based treatment asso-
ciated with expert-based recommendations.
treatment of alopecia areata deeming useful for the daily management of the disease. this article summarizes evidence-based treatment associ-
ated with expert-based recommendations.
(Cite this article as: rossi a, muscianese m, Piraccini Bm, Starace m, Carlesimo m, mandel Vd, et al. italian Guidelines in diagnosis and treatment 
of alopecia areata. G ital dermatol Venereol 2019;154:609-23. doi: 10.23736/S0392-0488.19.06458-7)
Key words: alopecia areata; Guideline; autoimmunity.
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hairs, corresponding to rapid catagen induction in aa. 
this category includes both “coudability hairs” and nor-
mal hairs with proximal tapered shape; they are usually 
detected in the perilesional area;
• Pohl-Pinkus constrictions: hairs characterized by 
zones of reduced hair thickness within the hair shaft. In 
aa the incidence rate of this feature ranges from 2 to 10% 
of patients;
• hair powder: fine pulverization of hair.
Trichoscopical signs of long-lasTing inacTive aa7
• Yellow dots: correspond to follicular ostium filled 
with keratin and/or sebum. They are seen as rounded or 
polycyclic dots of different sizes, with color ranging from 
whitish to brownish-yellow, usually lacking hair or less 
common short, thin hair shaft. When numerous, they are 
distributed in a regular matter; due to the underdevelop-
ment of sebaceous glands before puberty, yellow dots are 
not seen in children assuming a greyish color;
• exclamation mark hairs: can be present also in stable 
disease;
• short vellus hairs: short (less than 10 mm) and hypo 
pigmented hairs.
Trichoscopical signs ThaT indicaTe hair regrowTh7
• Upright regrowing hairs: they are healthy regrowing 
hairs that have a straight-up position and they can be con-
fused with short vellus hairs;
• pigtail hairs (circle hairs): short re-growing coiled 
hairs with tapered ends.
Reflectance confocal microscopy (RCM)9-12
rCm is a non-invasive imaging technique for in vivo eval-
uation of the skin and the observation of cell morphology 
with a nearly histological resolution. Hair shaft thickness, 
medulla, cortex and cuticle can be evaluated with RCM 
and the hair shaft structure abnormalities could be visual-
ized, as in trichoscopy, but with greater detail.
rCm features that can be observed in aa are:
• yellow dots: round luminal structures surrounded by 
follicular epithelium and filled by highly bright material 
corresponding to keratotic material and/or sebum;
• broken hairs: absence of follicular openings and 
presence of dysmorphic hairs that appear less bright then 
healthy hairs;
• exclamations mark hairs: short hyporeflective dys-
morphic hairs whose distal ends are broader than the prox-
imal ends;
parietal area sparing the temporal and occipital areas; (6) 
a diffuse pattern of hair loss and severe hair thinning that 
simulates androgenetic alopecia and telogen effluvium is 
typical of aa incognita; Finally a rare variant is (7) perine-
void aa. in some patients, aa may be localized to single 
hairy areas, such as the beard, eyebrows and eyelashes.
Usually, patients do not refer any symptoms, but occa-
sionally some cutaneous dysesthesia may precede or be as-
sociated with hair loss. The skin of the affected patches is 
usually normal and smooth, rarely a pinkish coloration can 
be detected. White hairs initially may be spared, leading to 
the appearance of sudden graying of the hair in extensive 
aa (canieties subita, maria antonietta Phenomenon, sud-
den hair whiting); regrowth may begin with the appear-
ance of fine white vellus hairs.
In addition, nails may be affected in AA, with geometric 
pitting being the most common sign, but also trachyonych-
ia, mottled lunulae, and rarely onychomadesis may occur.1
Trichoscopy
Hair and scalp dermoscopy (trichoscopy) represents a fast 
and non-invasive technique for the evaluation of hair loss 
that allows magnified visualization of the hair and of the 
scalp skin.5 Nowadays, trichoscopy is the most important 
tool for diagnosis of aa; moreover it is essential in the as-
sessment of disease activity and severity as well as thera-
peutic monitoring of aa.
in general, for aa diagnosis, short vellus hairs and yel-
low dots are the most sensitive markers, and black dots, 
broken hairs and tapering hairs are the most characteristic 
but not pathognomonic markers.6
Trichoscopical signs of acTive aa7
• Broken hairs: they result from irregular transverse 
fracture of the terminal hair of few millimeters from the 
scalp. The short length relates to the time between the lat-
est event of disease activity and the examination moment;
• black dots: black dots or cadaverized hairs represent 
fragments of hair within the follicular ostium due to acute 
hair matrix damage: they indicate active hair loss;
• flame hair: they are a residue of hair caused by a rapid 
and severe trauma of anagen hairs detectable in 21% of 
patients affected by aa;8
• exclamations mark hairs: mainly presents at the pe-
riphery of areas of hair loss, they are short, broken, dystro-
phic hairs whose distal ends are broader than the proximal 
ends. in our experience, they indicate a not recent mild 
damage to the follicle;
• tapered hairs: represent elongated exclamation mark 
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Rook identified three types: type I associated with atopy, 
starts in early life, and has a poor prognosis, type ii that 
starts after the age of 20, no associations are described and 
usually has a favorable prognosis and type iii, starts in 
adulthood has an intermediate prognosis and it is associ-
ated with autoimmune endocrine diseases (Figure 1).15
disease severity at onset of the disease is the strongest 
predictor of long-term outcome, especially alopecia totalis 
or alopecia universalis. other factors that are associated 
with a worse prognosis are onset in childhood, duration of 
more than one year, band-like involvement of the periph-
eral temporal and occipital scalp (ophiasis pattern), asso-
ciation with nail signs, association with atopy and family 
history of aa.
trichoscopic markers of activity can also be useful in 
predicting the course of disease and the assessment of re-
sponse to therapy. a large-scale study on the scalp of 300 
Asian patients showed that black dots, yellow dots, and 
short vellus hairs correlated with the severity of disease, 
and black dots, tapering hairs, broken hairs, and short vel-
lus hairs correlated with disease activity.6 in the author’s 
experience, also flame hairs and hair powder relates to dis-
ease activity.
Differential diagnosis
Several diseases need to be considered in the differential 
diagnosis of aa.
Patchy hair loss should be differentiated from:
• trichotillomania: this condition can be difficult to dis-
• black dots: round luminal structures with inside the 
remnant of dysmorphic hairs that look less reflective then 
healthy hairs;
• short vellus hairs: short hairs with a reduction of the 
caliber of the hair shaft in comparison to normal hairs;
• pigtail hairs (circle hairs): short coiled hairs with a 
reduction of the caliber of the hair shaft (< of 20 μm in 
diameter) and tapered ends;
• upright regrowing hairs: straight-up hairs with a re-
duction of the caliber of the hair shaft (< of 20 μm in di-
ameter);
• Pohl-Pinkus constrictions: hairs of normal thickness 
with irregularly placed thinner areas of the hair shaft (< of 
20 μm in diameter);
• inflammatory cells infiltration of epidermis, adnexal 
structure and upper dermis: small, single to aggregate and 
bright round cellular structure visible in the epidermis be-
tween keratinocytes, and/or within the adnexal epithelium, 
and/or in the upper dermis;
• rimmed dermal papillae: bright rimming of the der-
mal papillae that correspond on histology to the integrity 
and pigmentation of the dermoepidermal junction;
• melanophages: pumped, polygonal to stellate bright 
cellular structure in the upper dermis;
• dermal fibers degeneration: Coarse and thick dermal 
bundles of the upper dermis. this feature can be seen as 
diffused in the upper dermis or located around adnexal 
structures.
dilated vessels: horizontally oriented “canalicular” 
structures in the upper dermis.
in conclusion rCm is fundamental in the estimation of 
dermal fibrosis and inflammation measures, which are not 
assessable with tricoscopy, but are important parameters in 
the follow-up evaluation.
Scale of severity and prognosis
AA is a non-scarring alopecia and the regrowth capacity of 
hairs is preserved.
the severity of aa is assessed by the Severity of alo-
pecia tool (Salt) and graded according to the guidelines 
of the National alopecia areata Foundation13 as follows:
• S0: no hair loss;
• S1: less than 25% hair loss;
• S2: 26-50% hair loss;
• S3: 51-75% hair loss;
• S4: 76-99% hair loss;
• S5: 100% hair loss.
according to prognosis aa has been historically cat-
egorized into four types by ikeda14 and after on this basis, 
Figure 1.—Clinical types of alopecia areata. a) patchy alopecia; B) si-
saipho pattern; C) ophiasis pattern; d) alopecia totalis.
a
d
B
C
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i diabetes mellitus has also been reported in relatives of 
patients with AA.19 Iron deficiency was more common in 
women with AA than the general population in one small 
case serie.20 the implication of genes located on chromo-
some 21 is suggested by the association between an in-
creased risk for AA and genetic disorders such as Down’s 
syndrome (trisomy 21) and polyglandular autoimmune 
syndrome type i, caused by a mutation in the autoimmune 
regulator (aire) gene on chromosome 21.21-23 these re-
lationships between a broad spectrum of autoimmune dis-
eases imply a need for surveillance of patients for potential 
secondary autoimmune disease processes.
after diagnosis is made, a detailed personal and family 
history for atopy, thyroid disease, coeliac and other auto-
immune disorders should be obtained.
in the author’s opinion, all patients should be investigat-
ed at least for autoimmune thyroiditis and coeliac disease 
throw blood research of specific autoantibodies (anti-thy-
roid peroxidase antibodies and thyroglobulin antibodies 
and iga and igG antiendomysial antibodies and antitrans-
glutaminase antibodies).
Investigations
in most cases of aa, diagnosis can be made through ob-
taining a sound history and an accurate clinical inspection, 
especially since trichoscopy is available. a trichogram 
usually is not necessary. A positive pull test with dystro-
phic anagen or telogen hairs at the margins of the patches 
suggests activity of the disease along with trichoscopic 
signs of activity. Sometimes other investigations can be 
useful to rule out other differentials when clinical and 
trichoscopic features are not indicative.
When the diagnosis is uncertain appropriate tests may 
include microscopic examination of hair shafts and fungal 
culture, serology for lupus erythematosus or syphilis and 
scalp biopsy.
Histopathologic findings in AA change depending on 
the disease phase in which the biopsy is performed. In 
the early acute stage, the main feature is a peribulbar and 
intrabulbar lymphocytic infiltrate surrounding the anagen 
and/or catagen follicles described as “a swarm of bees.” 
The inflammatory infiltrate consists primarily of T cells 
(Cd4+, Cd8+) but langerhans cells, eosinophils, mast 
cells, and plasma cells can also be detected. this lympho-
cytic attack causes apoptosis, necrosis, and microvesicu-
lation of the follicular epithelium and anagen hairs cycle 
through catagen then into telogen.
In long-standing AA, inflammation is not constantly 
present. Horizontal sections are in these cases preferred 
tinguish from aa and a coexistent of the 2 condition is 
possible, especially in children. the main differences are 
2: the incomplete nature of the hair loss, that produce a 
bizarre shape of the alopecic areas and the fact that broken 
hairs are usually firmly anchored in the scalp, unlike ex-
clamation mark hairs, rending the pull test negative;
• tinea capitis: inflammation, scaling, pustules on the 
patchy hair loss suggest tinea capitis but the signs may be 
vanished.
Diffuse forms of AA need differential diagnosis with:
• telogen effluvium and anagen effluvium (drug and 
chemotherapy-induced);
• loose anagen hair.
Associated diseases
aa may be associated to several autoimmune and auto-
inflammatory disorders, such as thyroiditis and vitiligo, 
rheumatoid arthritis, systemic lupus erythematous, pso-
riasis, allergic rhinitis, type i diabetes, coeliac disease, 
myasthenia gravis, ulcerative colitis and scleroderma.1 
Furthermore, a high prevalence of other comorbid con-
ditions has been found among patients affected by aa16 
(table i).
Similarly to other autoimmune diseases, aa is char-
acterized by a strong genetic predisposition and several 
genes contribute to this risk. In AA three genome-wide as-
sociation studies showed that twelve independent genetic 
loci, including loci encoding genes in both innate and 
adaptive immunity, are involved. in particular, among the 
Hla class ii genes the dr4, dr5, dQ3, dQ7 and dPW4 
alleles are strongly associated.17, 18
interestingly an increased risk for autoimmune type 
Table i.— Summary of comorbid conditions in alopecia areata.
thyroid disease
Systemic lupus erythematosus
type 1 diabetes
diabetes mellitus
rheumatoid arthritis
Vitiligo
Psoriasis
myasthenia gravis
Coeliac disease
Ulcerative colitis
atopy (allergic rhinitis, asthma, eczema)
Contact dermatitis
mental health problems (depression or anxiety)
Hyperlipidemia
Hypertension
anemia
Gastroesophageal reflux disease
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Available therapies
Intralesional corticosteroids
Patients with isolated patches of hair loss or less than 25% 
of scalp hair loss are the best candidates of injections, due 
to the difficulty in tolerating a high number of injections 
in case of large areas. the affected area may be pretreated 
with a topical anesthetic cream under occlusion, or a fro-
zen gauze can be applied for a few seconds on the scalp 
before the injection to decrease pain.
There are no randomized trials on the efficacy of in-
tralesional corticosteroids in AA. However, two non-
randomized comparative studies found both intralesional 
triamcinolone acetonide and its less soluble derivative tri-
amcinolone hexacetonide effective in inducing re-growth 
of hair tufts with the effect of a single injection sometimes 
persisting for 9 months.27, 28
Intralesional treatment with triamcinolone acetonide by 
a needleless device has also been studied and showed good 
results.29
We recommend not to exceed the following concen-
trations of triamcinolone acetonide injected in the upper 
subcutis: 2.5 to 5 mg/mL on the face for eyebrow involve-
ment and 5 to 10 mg/ml on the scalp. multiple sites 1 cm 
apart are injected with small volumes of product. The total 
amount of triamcinolone administered should not exceed 
40 mg per treatment session. multiple treatment sessions 
can be planned after 30-45 days from each other. intrale-
sional steroid therapy should be discontinued if there is no 
response after six months.30 The well-known rare adverse 
effects of intralesional corticosteroids include reversible 
skin atrophy, telangiectasias and hypopigmentation, par-
ticularly in patients with type III-VI of Fitzpatrick skin 
type classification and disturbance of the menstrual cycle. 
In some specific sites such as eyebrows, it has been docu-
mented that intralesional corticosteroids may cause cata-
ract and elevation of intraocular pressure.31 Finally, two 
cases of anaphylaxis due to intralesional triamcinolone 
acetonide in literature are reported.32, 33 a signed informed 
consent should be asked before performing the procedure, 
which needs some experience.
Potent topical corticosteroids
They are considered first-line therapy in children and in 
adults with who refuse intralesional injections.34-36 While 
high potency topical corticosteroids are commonly used 
to treat aa, evidence for their effectiveness is limited, 
and data on efficacy are available only from two 12-week 
to vertical section as they provide more details, showing 
a significant decrease in the number of terminal hairs and 
in the anagen/telogen ratio. a chronic peribulbar lympho-
cytic infiltrate around the miniaturized hairs may also be 
observable.24
Therapeutic management
Counseling
an exhaustive explanation of the nature and course of the 
disease and the available treatments, discussing realistic 
expectations for treatment, is essential.
The quality of life should also be evaluated in patients with 
AA through DLQI questionnaire: hair loss can have signifi-
cant effects on patients’ quality of life and psychologic sup-
port is an important component of therapy. although aa has 
few physically harmful effects, it may lead to psychological 
consequences, including high levels of anxiety and depres-
sion. Studies of adolescents suffering from aa have found 
increased rates of psychiatric symptoms.25, 26 moreover, the 
failure treatment effects, not uncommon, may leave patients 
very distressed, particularly in children, adolescents, and 
young women. AA can also cause physical disability, such 
as when there is eyelash involvement, loss of nasal hairs, or 
marked nail dystrophy (twenty-nail dystrophy).
The problem with treatment AA is that its course is 
unpredictable. treatment of aa is not mandatory, conse-
quently the decision to treat is a shared decision with the 
patient; in view of the variable efficacy of currently avail-
able treatments and their respective side effects, the clini-
cian has an important role in making conscious patients 
of the positive and negative aspects of active treatment.
Patients must be informed about risks and benefits of 
treatment and that spontaneous remission occurs in up to 
variable percentage of patients with limited disease and 
the disease often recurs once the treatment is discontinued. 
it must be clear that none of the available treatments can 
modify the long-term course of the disease and a treatment 
with a specific indication for AA is still missing.
Objectives
• investigate and diagnose associated autoimmune dis-
eases;
• choose the specific treatment based mainly on age ac-
tivity and severity and of the disease;
• arrest the progression of the disease;
• induce of hair regrowth;
• limit side effects related to the therapy;
• improve the quality of life of patients.
aloPeCia areata roSSi
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better than alopecia totalis, universalis and ophiasis vari-
ety to these treatments.
Although significant side-effects have not yet been 
reported with pulsed systemic corticosteroids, the well-
known side effects associated with these agents and recur-
rence of the disease after their suspension limit duration of 
therapy.49, 50
Topical immunotherapy
Topical immunotherapy is the preferred first-line treat-
ment for patients with extensive chronic AA, assessed by 
trichoscopical signs. the precise mechanism of action of 
topical immunotherapy is not completely understood, but 
an immunomodulatory effect on the peribulbar infiltrate 
plays the key role. a potent contact allergen such as diphe-
nylcyclopropenone (dPCP) or squaric acid dibutyl ester 
(SADBE) is weekly applied on the scalp to stimulate an 
allergic mild contact dermatitis that in the end results in 
hair regrowth.51, 52
A recent systematic review and meta-analysis of for-
ty-five studies evaluating contact immunotherapy with 
1-chloro, 2, 4, dinitrobenzene (dNCB), diphenylcyclopro-
penone (dPCP) or squaric acid dibutyl ester (SadBe) for 
patchy aa, alopecia totalis, and alopecia universalis ana-
lyzed the results on 2227 patients. the overall rate of com-
plete hair regrowth was 32.3% while the overall rate of 
any hair regrowth was 65.5%. Similarly, to other therapies, 
patchy aa had better response rates than alopecia totalis 
or universalis. recurrences after treatment discontinuation 
were common (recurrence rates were 38.3% among pa-
tients receiving maintenance treatment and 49.0% among 
those not receiving maintenance treatment).53
Topical immunotherapy can be performed with DPCP 
or SADBE, while DNCB was found mutagenic. DPCP is 
usually preferred over SadBe because it is less expensive 
and more stable in solution. It must be stored away from 
light to avoid its degradation.
Protocol for DPCP use was described by Happle in 
1983;54 first of all, patients have to be sensitized by the 
application of a 2% dPCP solution to a small area, usually 
4x4 cm on the scalp, for 48 hours. After two weeks, treat-
ment can be started with application of DPCP to the affect-
ed areas, in a concentration that elicits a mild dermatitis, 
washed off after 24 hours. During the contact between skin 
and allergen, sun exposure is interdicted. the protocol for 
sensitization and treatment with SADBE is similar.
In the majority of studies if there was no response after 
six months therapy has to be discontinued; however, as 
hair regrowth with topical immunotherapy can occur even 
randomized trials. In the first one, 70 patients with patchy 
hair loss were randomly assigned to apply either placebo 
or 0.25% desoximetasone cream twice daily.37 after 12 
weeks of therapy 58% of patients treated with desoximeta-
sone experienced complete regrowth of hair compared 
with 39% of patients treated with placebo. These results 
failed to reach statistical significance. In the second study, 
105 patients with localized AA were randomized to treat-
ment with betamethasone valerate 0.1% foam applied 
twice daily, intralesional triamcinolone acetonide 10 mg/
mL administered every three weeks, or topical tacrolimus 
0.1% ointment applied twice daily. Results showed more 
than 75% hair regrowth in 54% of patients treated with be-
tamethasone valerate, 60% of patients treated with triam-
cinolone acetonide, and 0% of patients treated with topical 
tacrolimus.38 in a trial, 34 moderate to severe aa patients 
were randomly assigned to clobetasol propionate 0.05% 
application on one side of the scalp and a vehicle to the 
other side. After 12 weeks of treatment, more sites treated 
with clobetasol had at least 50% regrowth of hair.39 Clo-
betasol propionate cream placed under an occlusive dress-
ing was effective in 28,5% of the 28 patients of a study.40
After hair regrowth, potent topical corticosteroids must 
be tapered. there is no univocal protocol for this opera-
tion, which therefore must be based on the patient’s char-
acteristics and on the physician’s experience, individual-
izing the approach.
Similar to intralesional corticosteroids, side effects of 
topical therapy include folliculitis, local skin atrophy, tel-
angiectasias, dyspigmentation, and rarely adrenal suppres-
sion. Patients should be instructed to wash the head after 
12 hours from the application, in order to avoid steroid-
induced scalp folliculitis.
Systemic glucocorticoids
olsen et al. investigate in a prospective study of 32 pa-
tients with AA, including 16 patients with alopecia totalis 
or universalis, the efficacy of oral prednisone tapered from 
40 mg to 0 mg over the course of six weeks. 30-47% of 
patients treated showed more than 25% hair regrowth.41
The only one controlled trial of 43 patients that were 
treated with pulse 200 mg oral prednisolone or placebo 
once weekly for 3 months. After six months of predniso-
lone treatment, patients showed better results than those 
treated with placebo, but this was not statistically signifi-
cant.42
regimens that involve high-dose pulsed oral glucocor-
ticoids or even intravenous regimens may also induce hair 
regrowth.42-48 overall extensive patchy alopecia response 
roSSi  aloPeCia areata
616 GiorNale italiaNo di dermatoloGia e VeNereoloGia december 2019 
and universalis.63 In fact, a study that shows a significantly 
higher hair regrowth in patchy alopecia treated with topi-
cal 1% minoxidil compared with placebo,64 while other 
data suggest the opposite results.65, 66
However, a dose-response effect is documented, with 
a higher efficacy of 5% minoxidil compared to 1% min-
oxidil.67
Indication for the use of topical minoxidil in AA is when 
hair regrowth has started, in order to increase length and 
thickness of the new hair.
Biologic drugs
in the last years, several biologic agents have been consid-
ered as possible treatments for aa, thanks to their effec-
tiveness in several other autoimmune diseases. However, 
clinical trials on some antitumor necrosis factor (TNF)-α 
inhibitors such as infliximab and etanercept, or monoclo-
nal antibody such efalizumab and alefacept did not show 
the expected results.68-70 moreover, cases of acute aa oc-
curring during treatment with biologic agents are reported 
in literature.71-78
Janus Kinase inhibiTors
A relatively new class of biologic agents, Janus kinase 
(JAK) inhibitors appear to be effective in AA. Janus ki-
nases are critical for a large family of proinflammatory cy-
tokines signaling. The first JAK inhibitors have been ap-
proved by the FDA for the treatment of myelofibrosis, then 
rheumatoid arthritis.79 The most studied JAK inhibitor for 
the treatment of AA is an oral selective JAK 1/3 inhibitor: 
tofacitinib administered 5 to 10 mg twice daily.80-86 the 
results of these studies support the effectiveness in both 
patchy alopecia and alopecia totalis/universalis after only 
4 months of treatment. Lower efficacy was achieved in pa-
tients with a disease episode longer than 10 years (32% of 
clinical response rate).
Recently, two small case series were conducted to asses 
efficacy of oral tofacitinib in pediatric population. In the 
first study all of 8 children experienced partial hair re-
growth;87 in the other series, complete or partial hair re-
growth occurred in 3 of 4 preadolescent children treated 
for refractory alopecia totalis or universalis; of note, the 
non-responder was treated with half dose compared to the 
other children (5 mg daily instead of 5 mg twice daily).88 
Although no significant adverse effects were reported in 
either study, in our opinion, further studies are needed to 
confirm the safety and efficacy of tofacitinib before its use 
for pediatric alopecia. moreover, adverse effects reported 
lately, a 12-18 months of therapy length are suggested be-
fore assessing efficacy. In a large case series, hair regrowth 
occurred in about 30% of patients after 6 months of treat-
ment but this increased to 78% after 32 months of treat-
ment, suggesting that extension of treatment is useful.55
the main adverse effect of this treatment is the induc-
tion of a severe contact dermatitis characterized by vesic-
ular or bullous lesions. in this case, the contact allergen 
should be washed from the skin and treatment with a topi-
cal corticosteroid should be initiated. other possible side 
effects include occipital and or cervical lymphadenopathy 
(common), urticaria, dyschromia and vitiligo, especially 
in darker skin.56-59 the discontinuation of topical immu-
notherapy is recommended in pregnancy because until 
up today, no studies have defined its safety profile in this 
population.
Topical anthralin
anthralin or dithranol is a topical drug historically used 
for psoriasis therapy. anthralin action is carried out by re-
ducing inflammation. Evidence of its efficacy for AA is 
restricted to a small number of case series with inadequate 
controls.60, 61 Studies have suggested that anthralin may be 
effective high concentrations (0.5 or 1% cream) applied 
for short periods (20 to 30 minutes daily) on the alopecic 
scalp, in the so-called short-contact therapy. the time of 
contact is increased by 10 minutes every two weeks up to 
one hour or to the time required to produce a mild derma-
titis. Otherwise, treatment can also be started with appli-
cation of anthralin 0.1% to the scalp for 10 to 20 minutes 
and then gradually increasing this time of contact, reach-
ing tolerance for leaving anthralin on overnight. evidence 
shows that anthralin have to elicit a mild irritant reaction 
to be effective. anthralin should be used for at least three 
months. in 2015 a retrospective study demonstrated that 
combination therapy with DPCP and anthralin is more ef-
fective than dPCP monotherapy.62
Overall, a less percentage of patients with extensive 
AA achieved a good clinical response rate compared with 
intralesional corticosteroids and topical immunotherapy, 
and anthralin therapy is suggested in children who are too 
young to be treated with topical steroids.
Anthralin will stain hair, skin, and clothing brows, lim-
iting its use in fair-haired patients.
Minoxidil
data on effectiveness of topical minoxidil in aa resulting 
from randomized trials are contradictive, except for the 
evidence that minoxidil is not effective in alopecia totalis 
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on 75% or more of the scalp). of note, the occurrence of 
side effects such as diarrhea, liver enzyme elevation, pan-
creatitis, and bone marrow suppression resulted in treat-
ment interruption in four patients (28%).107, 108
Miscellaneous treatment
in the decades a miscellaneous group of topical and oral 
drugs with less scientific valence have been tested with 
variable results.
aromatherapy refers to the use of aromatic plant-based 
essential oils (thyme, rosemary, lavender, and cedar-
wood) for topical application onto the scalp. A random-
ized, double-blind, controlled trial of 7-month duration on 
86 patients from almost 2 decades ago, showed benefit 
of aromatherapy concluding that is a safe and effective 
treatment for aa.109 We do not recommend this therapy 
in aa.
Bexarotene is a selective retinoid that induces t-cell 
apoptosis. A phase I/II, randomized, single-blind trial, was 
conducted in 2010. Forty-two patients applied 1% bexaro-
tene gel twice daily for 6 months, to one side of the scalp. 
Five out 42 (12%) had 50% or more partial hair regrowth 
on the treated side, and 6 of 42 (14%) on both sides in-
cluding 3 complete responders.110 No further studies have 
been performed to suggest this drug a potential treatment 
for aa.
laser Therapy
the excimer laser is a form of ultraviolet laser that emits 
monochromatic ultraviolet B (UVB) light at a wave-
length of 308 nm. it is supposed that its mechanism of 
action in aa is related to t cell apoptosis.111 in the lit-
erature, some small studies and case reports showed an 
improvement of patchy aa after excimer laser treatment, 
also in children (60% response rate). However, alopecia 
totalis and alopecia universalis did not benefits from this 
treatment.111-114
The Infrared diode laser showed a good rate of response 
leading to a complete or partial regrowth in 32 out of 34 
treated patches.115
ezeTimibe-simvasTaTin
the statin family, usually used for reducing atherogenesis, 
have immunomodulatory activities. in a prospective study, 
19 patients assumed ezetimibe-simvastatin (10 mg/40 mg) 
once-daily for 24 weeks achieving 20% hair regrowth in 14 
cases and 70% of hair regrowth in 9 cases.116 Subsequent-
ly, a second phase of the study was conducted and patients 
during treatment with oral tofacitinib for other diseases 
include severe infections, malignancy and laboratory ab-
normalities.89, 90
in the open-label pilot study testing the effectiveness in 
AA of another JAK inhibitor, oral ruxolitinib at the dose 
of 20 mg, 75% of patients achieved at least 50% hair re-
growth after three to six months of therapy.89 Several other 
case series and case reports support the use of this drug in 
aa.91-95
The topical formulations of these new drugs (tofacitinib 
2% ointment, ruxolitinib 1% ointment) are very interest-
ing in order to minimize the adverse effects without losing 
effectiveness; nowadays few data are available but they 
seem to be a promising treatment option in both adults and 
pediatric aa patients.96-101
these drugs can be administered in both active and 
chronic phase of aa.
Systemic immunosuppressive agents
meThoTrexaTe
Methotrexate (10-25 mg per week) can be useful in AA, 
particularly when used in association with systemic gluco-
corticoids (clinical response rate of 63%).102 However, in 
order to achieve these results, therapy should be continued 
for three to twelve months, with an increased risk of drug 
toxicity and disease-recurrence commonly appears after 
discontinuation of methotrexate.
sulfasalazine
Several uncontrolled studies reported that this immuno-
suppressive drug is an efficacious therapy in approximate-
ly 25% of patients with AA.103-106 the open-label study 
conducted on 22 patients, 68.2% of patients responded 
to therapy (27.3% achieved complete hair regrowth, and 
40.9% achieved partial hair regrowth), concluding that 
sulfasalazine could be considered as a therapeutic alterna-
tive in the treatment of aa.103 Side effects of sulfasalazine 
may occur during treatment. thus, complete blood cell 
counts and liver function tests should be closely moni-
tored.
azaThioprine
azathioprine is an immunosuppressant agent that has been 
shown effective in stimulating hair regrowth in some pa-
tients with moderate to severe AA. However, the studies 
conducted are small and uncontrolled (almost 43% of the 
14 recruited patients experienced a good clinical regrowth 
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calcineurin inhibiTors
topical pimecrolimus and topical tacrolimus have not 
shown any result in AA treatment.127-129 Likewise, topi-
cal cyclosporine is not effective.130, 131 data from case se-
ries and uncontrolled studies on oral cyclosporine at high 
doses documented a possible hair regrowth in AA.132-135 
Similar to other immunosuppressive therapies, the poten-
tial serious adverse effects preclude a long-term therapy 
and must be considered.
fecal microbioTa TransplanTaTion
Two patients affected by alopecia universalis experienced 
hair regrowth after fecal microbiota transplantation.
authors suggest that gut microbiota may have immuno-
modulatory effects in autoimmune conditions like aa and 
further studies may elucidate this event.136
fumaric acid esTers
Fumaric aid esters are commonly used for psoriasis treat-
ment, thanks to their activities on cytokine networks.137 
For these immunomodulatory effects, Niculescu et al. has 
conducted a retrospective analysis of the application of fu-
maric acid esters in 13 patients with AA.138 Six (46%) pa-
tients had a response; 3 of them experiencing full regrowth 
of hair. Similarly to other treatments, patchy aa respond-
ed better than alopecia totalis or universalis: all patients 
experienced a new episode of hair loss after cessation of 
treatment, which is not advisable in AA, also considering 
the risk of fumaric acid esters toxicity.
oThers
Photodynamic therapy, azelaic acid, garlic gel, triiodo-
thyronine, isoprinosine and total glucosides of paeony 
are other treatment studied with no reported efficacy in 
aa.139
Topical prostaglandin analogues
there are no conventional treatments for eyelash alopecia. 
analogues of prostaglandin F2a, bimatoprost and latano-
prost, have been studied for eyelash loss with conflicting 
results. In literature, a 2-16 week controlled study shows 
no benefit with either latanoprost or bimatoprost140 and a 
partial regrowth in only one of 26 patients.141 lengthening 
the duration of treatment with latanoprost 0.005% ophthal-
mic solution every night for two years in 40 patients, a 
complete regrowth was achieved in 17.5%, moderate re-
growth in 27.5%, slight regrowth in 30% and no response 
were divided into responders who continued treatment for 
an additional 24 weeks and responders who stopped ther-
apy. in different case reports, alopecia totalis and alope-
cia universalis were successfully treated with simvastatin/
ezetimibe.117, 118 Recently, a prospective open study was 
performed in 14 patients with recalcitrant AA and authors 
concluded that the remission rate was unsatisfactory.119 in 
a prospective observational study on 12 patients treated 
with simvastatin/ezetimibe 40/10 mg over a period of 6 
months, 67% had no hair regrowth, 24% transient diffuse 
or patchy hair regrowth, and 24% patchy regrowth of pig-
mented hair. Side effects included myalgia reported by 
24% of patients and elevation of creatine phosphokinase 
in 1. authors conclude that simvastatin/ezetimibe is not 
effective for treatment of aa.120 We do not consider simv-
astatin/ezetimibe a suggested therapy for aa.
low-dose recombinanT inTerleuKin-2
interleukin (il)-2, a cytokine involved in regulatory t cell 
homeostasis, is historically used for the treatment of ad-
vanced melanoma and renal cell carcinoma. a small pilot 
study on five patients with AA showed a partial response 
in 4 of 5.121 The possible toxicity of low-dose recombinant 
il-2 therapy is, in our opinion, a limiting factor to suggest 
this therapy in aa.
plaTeleT-rich plasma (prp)
In the pilot study to investigate the efficacy and safety of 
PRP on AA, 45 patients with chronic and recurring dis-
ease were randomized to receive intralesional injections 
of PrP, triamcinolone acetonide or placebo on one half of 
their scalp. Platelet-rich plasma injection was most effec-
tive in inducing hair regrowth and decreasing scalp burn-
ing or itching sensation.122 the main side effects of PrP 
are pain, edema, tenderness, and rarely scalp psoriasiform 
reaction and scarring. Further studies are needed to sug-
gest this expensive therapy as a possible treatment for aa, 
based on its possible immunomodulatory action.
phoTochemoTherapy
Psoralen plus ultraviolet a (PUVa) photochemotherapy 
has been largely studied for treatment of aa.123-126 Some 
of these studies were uncontrolled and reported efficacy 
rates of 60 to 65% while others did not confirm these re-
sults, showing efficacy rates no better than the natural 
course of the disease without therapy. Moreover, cutane-
ous malignancy as long-term PUVa adverse effect cannot 
be ignored. We do not suggest PUVa as a therapy for aa.
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Patchy AA (less than 50% of scalp hair loss) in active phase
Intralesional and/or topical corticosteroids are definitely 
the first-line treatment when trrichoscopical signs of activ-
ity are present in the patch of hair loss, such as black dots, 
broken hairs, flame hair, hair powder. In specific cases, a 
short courses of systemic glucocorticoid can be added in 
order to temporarily halt disease progression.
We recommend systemic glucocorticoids only as a 
temporary measure to contain rapidly progressing active 
disease, when several trichoscopical signs of activity can 
be detected, with a conspicuous loss of hair; after reach-
ing this goal, these patients may be switched to alternative 
therapies. Common treatments course are 50 mg of pred-
nisone per day in adults or 1 mg/kg per day in children 
tapered over four to six weeks or 40 mg triamcinolone ace-
tonide intramuscular injection every 15 days tapered over 
6-12 weeks.
as mentioned above, desoximetasone, betamethasone 
valerate and clobetasol propionate are the only potent topi-
cal corticosteroids evaluated in the studies and thus recom-
mended.
However, based on the Author’s experiences, even the 
association of four different potent topical corticosteroids 
in different formulations can be considered. in this thera-
peutic schedule, the patients are instructed to apply topi-
cal corticosteroids in pairs, daily on alternate evenings. 
therefore, they apply triamcinolone acetonide solution 
and immediately after betamethasone cream on the first 
day. After one day off treatment, the association between 
salicylic acid and alcinonide lotion is administered im-
mediately prior to halometasone cream; they must have 
care in applying the lotion followed by the cream in order 
to facilitate the absorption of halometasone. this proto-
col can be helpful to avoid a sudden decrease in response 
(tachyphylaxis).
High potency topical corticosteroids should be used for 
3 to 6 months before judging its effectiveness, and can be 
extended also in the maintenance treatment with lengthen-
ing of time of application.
Patchy AA (less than 50% of scalp hair loss) in chronic phase
Patients with Patchy AA in chronic stage, or patients not 
responding to topical corticosteroids, can be treated with 
topical immunotherapy with the same regimen described 
for patients with more extensive disease. Another option 
in this category should be the association between topical 
minoxidil 5% and topical anthralin as well as the associa-
tion between topical immunotherapy and topical anthralin.
in 25%. in the control group, none of the patients treated 
with injections of 0.5 mg/cm2 of triamcinolone acetonide, 
reached similar results.142
Cosmetic options
Wigs, headscarves, hairpieces, shaving of the scalp, tat-
toos, tricopigmentation, protein powders, sprays, or pig-
mented lotions designed to make the hair appear more full 
are very helpful to decrease the patient’s perception of aa 
and should be suggested, as well as the application of false 
eyelashes and eyebrows.
Treatment management
in the authors’ opinion, the treatment approach of patients 
with AA should differ based upon the age, the clinical ex-
tent and the activity of the disease.
in patients younger than 10-years, regardless of the clin-
ical manifestation, topical high potency corticosteroids are 
the preferred treatment. eventually, minoxidil 5% can be 
added.143 anthralin can be considered in very young chil-
dren (1-3 years) (Figure 2).
over 10-years old of age, the activity and extent of dis-
ease should be considered.
Figure 2.—treatment algorithm for the management of alopecia areata.
Ccs: corticosteroids; imt: immunotherapy; mtX: methotrexate; aZP: 
azathioprine.
Over age 10
-  Topical Ccs ± 
minoxidil 5%
- Anthralin
Under age 10
Age
-  Intralesional 
and/or topical 
Ccs
-  Systemic 
Ccs (only if 
needed)
Patchy,  
Active phase
Patchy,  
Chronic phase
Severe,  
Active phase
Severe,  
Chronic phase
-  Topical IMT
-  Minoxidil 5% + 
Anthralin
-  Topical IMT + 
Anthralin
-  Topical 
Ccs (under 
occlusion)
- Systemic Ccs
- MTX or AZP
- Topical IMT
-  Topical 
Ccs (under 
occlusion)
Extent + Activity
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Guidelines useful and needed for the daily management 
of the disease and for the future acknowledge of AA a real 
immunological disease by italian National Health Service.
as the response to treatment of aa is variable, and 
some patients may choose do not undergo under treatment, 
a conscientious approach evaluating all the mentioned as-
pects is essential when dealing with patients with all types 
and severity of aa.
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Severe AA (more than 50% of scalp hair loss) in active phase
In patients with extensive AA that shows trichoscopical 
signs of activity (black dots, broken hairs, flame hair, 
hair powder), the first-line treatment should be systemic 
glucocorticoid, prescribed in short course as mentioned 
above.
in addition, high potency topical corticosteroids such 
as desoximetasone, betamethasone valerate and clobeta-
sol propionate placed under an occlusive dressing to 
increase their effects, should be used. even in these pa-
tients the authors have experiences with the association 
of four different potent topical corticosteroids in different 
formulations (triamcinolone acetonide, betamethasone, 
association between salicylic acid and alcinonide, halo-
metasone).
if corticosteroids failed in to contain the disease, a sec-
ond line choice could be a systemic immunosuppressant, 
among methotrexate and azathioprine. However, take into 
account all the possible adverse effects of these therapies, 
an accurate evaluation of the patient is essential before 
starting these treatments.
Severe AA (more than 50% of scalp hair loss) in chronic 
phase
topical immunotherapy is the treatment of choice in these 
patients with by severe AA with trichoscopical signs of 
chronic phase (yellow dots, exclamation mark point hair, 
short vellus hair). alternatively, high potency topical cor-
ticosteroids in occlusion can be proposed.
Conclusions
the main goals of treatment in aa are to block the im-
mune system attack and to stimulate the regrowth of hair. 
This can be effective, especially for people with milder 
forms of the disease, while extensive forms often fail to 
respond to therapy.
Only a few treatments for AA have been evaluated in 
randomized clinical trials and the majority of them are 
characterized by few recruited patients, with several stud-
ies having major limitations that hinder the interpretation 
of the results. therefore, there is relatively little evidence 
on treatment of AA from well-designed clinical trials.
moreover, none of the treatments or devices commonly 
used to treat AA are specifically approved by the Food and 
drug administration (Fda) and are not refunded by the 
italian National Health Service.
For all these reasons the authors consider the italian 
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